Research programme: selective estrogen receptor-beta agonists - Karo Pharma
Alternative Names: KB093823; KB095285; KB095508; KB099520; KB285; KB9520; KB9580Latest Information Update: 10 Apr 2023
Price :
$50 *
At a glance
- Originator Karo Bio
- Class
- Mechanism of Action Selective estrogen receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Multiple sclerosis
Highest Development Phases
- No development reported Cancer; Genitourinary disorders; Mesothelioma; Multiple sclerosis
- Discontinued Major depressive disorder
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for preclinical development in Mesothelioma in Sweden (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Sweden (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Genitourinary-disorders in Sweden (PO)